Trial Profile
A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Jul 2020 Status changed from active, no longer recruiting to completed.
- 16 Jun 2020 Planned End Date changed from 28 Mar 2020 to 19 Jun 2020.
- 26 Jul 2019 Planned End Date changed from 15 Aug 2019 to 28 Mar 2020.